15 ms·
Crispr Wins Key Approval to Fight Cancer in Human Trials
- zymhan 10y agoI hope that by the time I'm succumbing to the effects of aging, we'll have techniques with tools like CRISPR to make it easier.
- CodeCube 10y agoI'll see you at my 1000th birthday party! high fives
- lallysingh 10y agoOw! Not so hard!
- Aelinsaar 10y agoIt seems likely, assuming a couple of decades before you're "succumbing".
- themartorana 10y agoWho knows... Ain't that the mystery?
- ddorian43 10y agoAnd are you doing something about it (donating/investing/working/etc) ?
- ceejayoz 10y agoChances are anyone in a developed-world democracy is investing/donating via their tax dollars.
- JoshTriplett 10y agoNot very effectively or with the focus you might want, though.
- ceejayoz 10y agoI tend to believe the NIH is better at administrating grants than I am.
- JoshTriplett 10y agoI'd absolutely agree they're better than I am personally, since I'm neither a medical researcher nor an expert at evaluating medical research. But I don't believe they're better than an organization focused on solving a specific problem. As a random example of inefficiency: there's a lot more money going into research on specific degenerative diseases than into the causes and solutions for degeneration. Solve the root cause, not the symptoms.
- ejstronge 10y agoWhile the idea of pursuing a 'root cause' is attractive, in many cases, including the one you point out, there is not a clear cause to be attacked. Neurodegeneration is a pattern of response to multiple disease processes - we can only understand the response by studying the cases in which it arises. For the tech-minded crowd, this is like wanting to create responsive designs without actually making websites to demonstrate them.
- reasonattlm 10y agoThey're actually pretty terrible. It isn't a high bar to do better than the NIH when it comes to supporting new technologies. Almost all important early fundamental research, the high-risk part leading up to new knowledge and potential new technologies, is supported by philanthropy. The NIH really only funds follow-on work for things that are already known. In order to win a grant you have to have already proven your thesis. It is somewhat ridiculous. So if you want to delegate your vote, delegate it to a non-profit. Or invest in a startup in the field you care about. Anything other than giving to the NIH.
- JoshTriplett 10y agoI'm sad to see this downvoted. It's reasonable to try to turn expressions of support on a forum into action. For anyone who wants to support research into ending aging, age-related degeneration, and related diseases, I'd recommend supporting SENS (http://www.sens.org/ http://www.sens.org/).
- davesque 10y agoOff-topic: is your account named after the diatonic scale? I love the dorian scale.
- gozur88 10y agoYou don't have to be old to get diseases. The way I see it a few aches and pains are a small price to pay for not being dead.
- astazangasta 10y agoI'm calling it here, this trial will fail hard. The basic idea is this: the cancer has a number of mutations that produce novel antigens that don't exist in normal cells. If we can train T-cells to recognize these, they can attack the tumor with great specificity and kill those cells. The problem is, all the tumor has to do to evade this targeting is shed the problematic mutation, which is easily done - tumors are great at acquiring novel mutations to become resistance to therapy, losing a mutation is even easier. All you have to do is ditch one arm of a chromosome, revert the mutation, or otherwise eliminate the novel mutation, and your tumor cell is now resistant to this therapy. Add to this the fact that we are basically shit at predicting which mutant proteins will produce neoantigens and you have a recipe for total failure, even in concept.
- return0 10y agoHow long will this process take? Is it enough to create a new therapy to target the mutated cancer?
- astazangasta 10y agoPeople develop resistance to TKIs (tyrosine kinase inhibitors, the previous mode of therapy) within months; you could keep chasing the dragon, but the tumor is just going to keep doing the same thing, shedding whatever mutation you target. In this case you're not even targeting mutations that the tumor relies on (as you are with a TKI), so there's absolutely no fitness cost to the tumor to evade.
- return0 10y agoBut what if the antigens are vital for the tumor ? What mutation are you referring to? Presumably the immune system will kill the cancerous cells ( shedding the mutation as well).
- darawk 10y agoCould you simultaneously target multiple mutations to reduce the risk of this? Similarly to using a cocktail of antibiotics to prevent the development of resistance. i.e. the probability of shedding a single mutation is 1/x, but the probability of shedding two in the same organism is (1/x)^2, so targeting more mutations make it exponentially harder for the organism to adapt.
- c-slice 10y agoIf you want to better understand the CRISPR patent dispute, this article lays out the arguments very clearly. https://www.statnews.com/2016/03/18/crispr-patent-dispute/ https://www.statnews.com/2016/03/18/crispr-patent-dispute/
- SapphireSun 10y agoHa, are you sure you didn't mean http://www.cell.com/cell/fulltext/S0092-8674(15)01705-5 http://www.cell.com/cell/fulltext/S0092-8674(15)01705-5 ;D (For those of you who aren't in on the joke, "The Heroes of CRISPR" was written by the director of the Broad Institute, which incidentally has Feng Zheng on its payroll. For that reason Eric Lander has been roundly criticized for attempting to weigh in on the history early. My friends who work in and around Kendall Square say that some of the criticism is overblown, the article points out a lot of people who didn't get much recognition prior, but still... it's a bit skeevy so you might want to take the latter half of the article with a grain of salt as it's not necessarily factually wrong, but the emphasis might be distorted and there is a risk of omissions.)
- Obi_Juan_Kenobi 10y agoIt might be a good legal overview (I wouldn't know), but the scientific merit is overwhelmingly in Doudna's favor. The actual novelty and value of the method is the ability to edit nucleotides, not whether it can be done in prokaryotes vs. eukaryotes. In the case where this was a known technique that had significant difficulties in translating to eukaryotic work, then the Broad Institute's work would be significant. That was not, however, the case. Very little needed to change, and the technique has been widely applicable. Just a quick look though Doudna's publications shows that this is an issue with a great deal of background work behind it, years of effort that fortuitously resulted in an incredible invention. Then, someone comes along, copies your work in some different bugs, and claims ownership. It's really no more complicated than that.
- VeejayRampay 10y agoWhy doesn't the article mention Emmanuelle Charpentier?
- baldfat 10y agoHaving lost a sister and a son to cancer I hope for this to work. The issues are tremendous for this technique and I don't have high hopes for its use on cancer. I am still having high hopes on immune system techniques that helps the body to mark cancer cells and attack the cells for most cancers. CRISPR big hope is that it can change the cell to stop reproducing or stop invading other cells. Simply put cancer cells are cells that grow that don't stop AND can spread to other cells. If you get one of the two you win. HIGHLY RECCOMENDED : list to Radio Lab Famous Tumors http://www.radiolab.org/story/91713-famous-tumors/ http://www.radiolab.org/story/91713-famous-tumors/
- j_jochem 10y agoIsn't the idea with CRISPR that you patch the patient's t-cells in such a way that they are able to recognize cancer cells as diseased cells, allowing the immune system to clear them away?
- alextheparrot 10y agoThe holy grail would be fixing commonly occurring mutations that cause the cancer, but to my knowledge the edit/correction rate is too low for this to work currently, plus the possibility of causing more cancer by bad edits. Thus, the T-cell approaches are more promising currently as it allows for direct modification of cells to fight cancer with known anti-cancer antigens, using a modified immune system.
- 10y ago
- cioc 10y agoIf you think stuff like this is cool, and you'd like to be a part of the software engineering effort at Parker Institute for Cancer Immunotherapy, msg me. ccary@parkerici.org We are building out our platform for bioinformatics. Some engineering topics: * Large scale data processing (Cloud & on-prem HPC based) * Bioinformatics / ML algorithms * Data storage & retrieval (File systems & databases)
- vosper 10y agoI think this is cool! Are there any particular software engineering skills or experiences that would be really valuable or relevant to this work?
- wfunction 10y agoYes, please elaborate on what the software engineering effort involves! Is this a bioinformatics thing? What kind of work does it involve? Does it require a strong theoretical background? etc. (Edit: Thanks! Just noticed you added it.)
- leeoniya 10y agomaybe WRT to https://www.google.com/search?q=genome+sequencing+algorithms https://www.google.com/search?q=genome+sequencing+algorithms which would be needed to find unique patterns among billions of base pairs for CRISPR to target. it's microscopic big data :D [1] http://benchling.engineering/dna-regex-search/?hn http://benchling.engineering/dna-regex-search/?hn [2] http://benchling.engineering/optimizing-crispr/ http://benchling.engineering/optimizing-crispr/
- deleted 10y ago[deleted]
- ghc 10y agoSeems like this is something you might use the Church lab's spinoff Curoverse for?
- godbov 10y agoI've got a background in machine learning (NLP, and a little bit of vision) and electrical engineering, but I know very little about biology. Essentially, all I know is a working knowledge based on what I remember from high school. However, I'm incredibly fascinated by some of these recent developments in making biology more computational! I've started working through some Coursera courses on bioinformatics systems biology, and have been totally engrossed so far! I noticed that the Parker Institute is a non-profit? I was curious what kind of ramp-up path you offer people like me, with a background in ML, and are excited to learn some more biology if they join the team? Since you're a non-profit, I was wondering if there'd be any interest in helping to curate a bunch of links/resources/etc. so people like me can learn and ramp-up in our spare time? I guess I'm wondering if it's difficult to hire for this role. So maybe other non-profits, e.g. J. Craig Venter Institute may also be interested in helping to curate these resources to help increase supply of possible hires?
- Dowwie 10y agoWell, it's worth a shot. http://i.imgur.com/BbgL7x3.gif?noredirect http://i.imgur.com/BbgL7x3.gif?noredirect
- DigitalSea 10y ago>rewrite the blueprints of life itself Something unsettling about how that is worded, but this awesome. There hasn't really been any major breakthrough like this in a very long time, as the era of antibiotics ends, new treatments like this might open the door for a new wave of medical treatments.
- noam87 10y agoAs someone about to start PD-1 inhibitors after failing Ipilimumab (now in lungs (1))... well it'd be just plain stupid to die now with all these treatments on the horizon. --- (1) This just happened this month. The Doctor called me with the results literally the week after I handed in my notice at a secure job to join an early-stage startup. Life really is short! (http://www.paulgraham.com/vb.html http://www.paulgraham.com/vb.html) No I don't regret my decision :) (Also thank Jeebus I live in Canada where my current lack of benefits does not preclude me from getting the best treatment.)
- victoriadanahy 10y agoNo doubt, CRISPR is the next big thing that will make sense for everyone. I work for Synthego and we make synthetic RNA for CRISPR/Cas9 Genome Engineering. Our process is fully automated with robots and an architected LAB synthesizer. We are actively hiring: * Full Stack Engineers with strong DB and Python skillS * Robotics/Mechanical Engineers with automation experience AND who think outside the box! *Extraordinary Human Beings are welcome too If you are interested --> email me: victoria.danahy@synthego.com :-)